Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
NCT05751759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31
Last updated 2024-12-05
Summary
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
Conditions
- Hepatic Impairment
Interventions
- DRUG
-
Mitiperstat
Participants receive mitiperstat orally.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-20
- Primary Completion
- 2024-11-21
- Completion
- 2024-11-21
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
NCT01579461 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study in Patients With Impaired Hepatic Function
NCT02586194 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
NCT01516047 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function
NCT02001571 ·Status: COMPLETED ·Phase: PHASE1
-
Tepotinib Hepatic Impairment Trial
NCT03546608 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
NCT00382668 ·Status: COMPLETED
-
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234 ·Status: COMPLETED ·Phase: PHASE1
-
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
NCT03968848 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone
NCT06388616 ·Status: COMPLETED ·Phase: PHASE1
-
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
NCT04154774 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
NCT06997276 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
NCT01197911 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
NCT03040479 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
NCT04859426 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
NCT01767688 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
NCT05097716 ·Status: COMPLETED ·Phase: PHASE1
-
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942 ·Status: COMPLETED ·Phase: PHASE1
-
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
NCT01901133 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196
NCT04867941 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
NCT02857868 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function
NCT05126329 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants
NCT01655147 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
NCT04991571 ·Status: COMPLETED ·Phase: PHASE1